Q-omics provides the consensus-scored GARRE1 profile across patient tissues and cancer cell-line models. GARRE1 expression is associated with patient survival in 32 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GARRE1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, GARRE1 RNA expression shows 20,429 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where GARRE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GARRE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GARRE1 survival associations across molecular data types. GARRE1 RNA expression shows survival associations in the most cancer types (32), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GARRE1 RNA expression–survival associations across cancer types. High GARRE1 expression shows unfavorable associations in MESO, ACC and LGG, but favorable associations in KIRC, UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GARRE1 RNA expression.
This table summarizes GARRE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GARRE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GARRE1 shows lower tumor expression in KICH, LUSC, LUAD, BRCA and UCEC and higher tumor expression in LIHC. The KICH box plot shows higher GARRE1 RNA expression in normal versus tumor tissue (log2 FC = −1.081, t-test p < 0.001).
This table shows molecular features associated with GARRE1 in patient tissues and cancer cell lines. In patient samples, GARRE1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GARRE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
